Zila's OraTest Rinse Needs Additional Study, FDA Advisory Committee Says
This article was originally published in The Gray Sheet
Executive Summary
Zila should conduct another trial of its OraTest oral cancer diagnostic, FDA's Oncology Drugs Advisory Committee determined Jan. 13.
You may also be interested in...
Zila’s OraTest Oral Cancer Screen Lags At CDER; ZTC Clears Premarket Hurdle
Zila Medical's strategy of seeking an adjunctive claim for its ZTC tolonium chloride compound enabled a relatively quick device review, CEO Douglas Burkett said in a Feb. 7 conference call
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.